PVLA
What one share of Palvella Therapeutics holds
Pharmaceutical Preparations
On December 13, 2024, we completed the previously announced business combination with Legacy Palvella in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Palvella, with Legacy Palvella surviving as our wholly owned subsidiary (such business combination, the Merger).
Palvella Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.90 |
|---|---|
| Cash and investments | $13.05 |
| Book value | $15.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.14 | −$0.55 | $0.01 | −$0.36 | — | $0.59 |
| 2017 | $0.58 | −$0.40 | $0.04 | $1.09 | — | $0.26 |
| 2018 | $0.55 | −$0.50 | $0.03 | −$0.05 | — | $0.74 |
| 2019 | $0.91 | −$0.56 | $0.05 | −$1.08 | — | $0.93 |
| 2020 | $0.54 | −$0.68 | $0.05 | −$0.89 | — | $0.55 |
| 2021 | $0.49 | −$0.71 | $0.01 | −$0.13 | — | $0.70 |
| 2022 | $0.35 | −$0.45 | $0.01 | −$0.82 | — | −$1.26 |
| 2023 | $23.86 | $2.17 | $0.10 | −$7.73 | — | −$42.08 |
| 2024 | — | −$7.83 | — | −$4.87 | — | — |
| 2025 | — | −$3.71 | — | −$2.22 | — | $2.26 |